Suppr超能文献

相似文献

1
Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass.
J Obstet Gynaecol India. 2015 Apr;65(2):117-21. doi: 10.1007/s13224-014-0609-1. Epub 2014 Oct 7.
3
Evaluation of the risk malignancy index diagnostic value in patients with adnexal masses.
Vojnosanit Pregl. 2011 Jul;68(7):589-93. doi: 10.2298/vsp1107589t.
7
Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index.
J Obstet Gynaecol Res. 2009 Feb;35(1):131-8. doi: 10.1111/j.1447-0756.2008.00869.x.
8
Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
Gynecol Endocrinol. 2012 Jun;28(6):478-82. doi: 10.3109/09513590.2011.633663. Epub 2011 Nov 28.
9
Risk of malignancy index in the evaluation of patients with adnexal masses.
J Obstet Gynaecol Can. 2009 May;31(5):440-5. doi: 10.1016/s1701-2163(16)34175-5.
10
Risk of malignancy index validity assessment in premenopausal and postmenopausal women with adnexal tumors.
Taiwan J Obstet Gynecol. 2013 Jun;52(2):253-7. doi: 10.1016/j.tjog.2013.04.017.

引用本文的文献

1
Advancements in artificial intelligence for ultrasound diagnosis of ovarian cancer: a comprehensive review.
Front Oncol. 2025 Jun 12;15:1581157. doi: 10.3389/fonc.2025.1581157. eCollection 2025.
2
The frequency and characterization of ovarian metastasis from nonovarian cancers using 18F-fluorodeoxyglucose PET/CT.
BJR Open. 2025 Mar 18;7(1):tzaf004. doi: 10.1093/bjro/tzaf004. eCollection 2025 Jan.
3
Quantifiable TCR repertoire changes in prediagnostic blood specimens among patients with high-grade ovarian cancer.
Cell Rep Med. 2024 Jul 16;5(7):101612. doi: 10.1016/j.xcrm.2024.101612. Epub 2024 Jun 14.
4
Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.
Front Mol Biosci. 2024 Apr 16;11:1361601. doi: 10.3389/fmolb.2024.1361601. eCollection 2024.
5
Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
Br J Cancer. 2024 Jun;130(10):1716-1724. doi: 10.1038/s41416-024-02644-4. Epub 2024 Apr 24.
6
A Comprehensive Review of Screening Methods for Ovarian Masses: Towards Earlier Detection.
Cureus. 2023 Nov 8;15(11):e48534. doi: 10.7759/cureus.48534. eCollection 2023 Nov.
9
OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer.
Clin Cancer Res. 2023 Dec 15;29(24):5196-5206. doi: 10.1158/1078-0432.CCR-23-1197.
10
Accuracy of the risk of malignancy index-I in diagnosing ovarian malignancy in menopausal women.
Prz Menopauzalny. 2023 Mar;22(1):1-5. doi: 10.5114/pm.2023.126435. Epub 2023 Apr 3.

本文引用的文献

2
Comparison of four malignancy risk indices in the detection of malignant ovarian masses.
J Gynecol Oncol. 2011 Sep;22(3):177-82. doi: 10.3802/jgo.2011.22.3.177. Epub 2011 Sep 28.
3
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.
Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8. doi: 10.1158/1940-6207.CAPR-10-0402.
5
Who should operate on patients with ovarian cancer? An evidence-based review.
Gynecol Oncol. 2005 Nov;99(2):447-61. doi: 10.1016/j.ygyno.2005.07.008. Epub 2005 Aug 29.
6
Screening postmenopausal women for ovarian cancer: a systematic review.
J Obstet Gynaecol Can. 2004 Aug;26(8):717-28. doi: 10.1016/s1701-2163(16)30643-0.
9
Comparison of three risk of malignancy indices in evaluation of pelvic masses.
Gynecol Oncol. 2001 May;81(2):225-9. doi: 10.1006/gyno.2001.6122.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验